Shape Therapeutics
Shape Therapeutics develops programmable RNA medicines that use AI and RNA technology to address genetic causes of disease. Its work includes RNA editing, next-generation AAV delivery and gene therapy manufacturing for pharmaceutical innovators developing treatments for rare genetic disorders and other diseases.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2018
- Type
- Corporation Seattle business license
- Employees
- 51–200
- Registered name
- Shape Therapeutics Inc Seattle business license
- Stage
- Series B
Is this your organization? Claim it
Shape Therapeutics and Rett Syndrome Research Trust partner to advance SHP-401 AI-designed RNAfix® therapy correcting MECP2 R168X toward IND studies
Shape Therapeutics and the Rett Syndrome Research Trust partnered to fund translational studies of SHP-401, an intravenously delivered, one-time RNAfix® gene therapy using AI-designed guide RNA to correct the MECP2 R168X mutation for Rett syndrome. Preclinical mouse data posted to bioRxiv show ~70% RNA editing in the brain and restoration of full-length MeCP2 after a single IV dose, supporting IND-enabling study goals in non-human primates.
People
-
David Huss Executive, Chief Scientific Officer and Interim CEO
-
Francois Vigneault Former founder